Ras, PI(3)K and mTOR signalling controls tumour cell growth
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
All eukaryotic cells coordinate cell growth with the availability of nutrients in their environment. The mTOR protein kinase has emerged as a critical growth-control node, receiving stimulatory signals from Ras and phosphatidylinositol-3-OH kinase (PI(3)K) downstream from growth factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen availability. Notably, components of the Ras and PI(3)K signalling pathways are mutated in most human cancers. The preponderance of mutations in these interconnected pathways suggests that the loss of growth-control checkpoints and promotion of cell survival in nutrient-limited conditions may be an obligate event in tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
From Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008) · cites this paper as [13]
In the citing paper
“PI3K signaling may be central to linking the common genetic perturbations of cancer, such as RTK mutations and PTEN loss, with altered metabolic processes, including the “lipogenic phenotype” common to many cancers, including GBM (13, 14, 17, 20).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [20]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 8×
“So, the PI(3)K heterodimer is recruited to the membrane to generate local pools of PtdIns(3,4,5)P3.”
BackgroundInfluentialAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · cited 1×
“AMPK inhibits mTOR at least in part by the direct phosphorylation of tuberin ( Box 3 ), and cells that lack tuberin retain activated mTORC1 under conditions of low glucose as well as hypoxi”
BackgroundRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 1×
“In addition to loss of RasGAP function, Ras activity is reported to be elevated through reduced expression of a conserved microRNA (let-7) that targets the 3′ untranslated region of H-ras, N-ras and K-ras messenger RNA”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 1×
“PTEN catalyses removal of the D3 phosphate from PtdIns(3,4,5)P 3 (the reverse of the reaction catalysed by PI(3)K) to limit and ultimately terminate PI(3)K signalling in cell”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“The existence of the S6K-based negative-feedback loop means that prolonged rapamycin treatment will probably lead to enhanced PI(3)K–AKT activation in some tumours, as has been observed in several tumour cell lines grown in culture, and in tissues from patients in clinical trials of rapamycin analogue”
BackgroundRoux, P. P., & Blenis, J. (2004) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.68.2.320-344.2004 · Cited by 2,490
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006 · cited 1×
“Sporadic mutations of PTEN are found in a high percentage of many tumour types, including breast, ovarian and colon cancers and glioblastom”
BackgroundSelf-citationThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Self-citationInterleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt
Peso, L. D., González-Garcı́a, M., Page, C., Herrera, R., & Nuñez, G. (1997) · Science · doi:10.1126/science.278.5338.687 · Cited by 1,797 · cited 1×
“AKT also controls cell survival through its inactivation of the pro-apoptotic protein BA”
BackgroundShaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
Self-citationAbsence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., & Hardie, D. G. (2003) · Journal of Biology · doi:10.1186/1475-4924-2-28 · Cited by 1,665 · cited 1×
“LKB1 encodes a threonine kinase that was shown genetically and biochemically to be the direct activating kinase for the AMP-activated protein kinase (AMPK), a mediator of cellular and organismal metabolis”
BackgroundA serine/threonine kinase gene defective in Peutz–Jeghers syndrome
Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A., Bignell, G., Warren, W., Aminoff, M., Höglund, P., et al. (1998) · Nature · doi:10.1038/34432 · Cited by 1,656 · cited 1×
“LKB1 is a tumour suppressor that is mutated in the familial cancer disorder Peutz–Jeghers syndrome, as well as in a large percentage of sporadic lung adenocarcinoma”
BackgroundLKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
GSK3 takes centre stage more than 20 years after its discovery
FRAME, S., & COHEN, P. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590001 · Cited by 1,433 · cited 1×
“Glycogen synthase kinase-3 (GSK-3) is a highly conserved protein kinase that is inhibited by AKT phosphorylatio”
Background(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356 · cited 1×
“Conversely, FOXO proteins are activated under stress conditions, accumulating in the nucleus and driving the expression of pro-apoptotic genes as well as stress-response genes, such as superoxide dismutase ( SOD2 ), that contribute to lifespan extension in lower metazoan”
BackgroundTargeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Self-citationPhosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123 · cited 1×
“Subsequently, in both flies and mammals, TSC-deficient cells were found to have extremely low levels of AKT activation, even after growth-factor stimulation, despite high mTORC1 activit”
BackgroundThe LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077 · cited 1×
“However, in cells that lack LKB1, mTORC1 remains active because the AMPK checkpoint is defectiv”
BackgroundSelf-citationRheb Binds and Regulates the mTOR Kinase
Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., & Avruch, J. (2005) · Current Biology · doi:10.1016/j.cub.2005.02.053 · Cited by 1,005
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951 · cited 1×
“However, they found that overexpression of eIF4E (the binding partner of the mTORC1-regulated protein 4EBP1) avoided the rapamycin inhibition of growt”
BackgroundRole of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915 · cited 1×
“Investigations of the most frequent p110α tumour mutations have shown that they enhance PI(3)K activity and drive cell transformatio”
BackgroundGao, T., Furnari, F., & Newton, A. C. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.008 · Cited by 906 · cited 1×
“PHLPP, a newly identified phosphatase containing a lipid-binding PH (pleckstrin homology) domain, specifically dephosphorylates Ser 473 of AK”
BackgroundThe Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821 · cited 1×
“and perhaps competition between the rictor-mediated and raptor-mediated assembly of mTOR complexe”
BackgroundSun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802 · cited 1×
“The existence of the S6K-based negative-feedback loop means that prolonged rapamycin treatment will probably lead to enhanced PI(3)K–AKT activation in some tumours, as has been observed in several tumour cell lines grown in culture, and in tissues from patients in clinical trials of rapamycin analogue”
BackgroundGarnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799 · cited 8×
“So, the PI(3)K heterodimer is recruited to the membrane to generate local pools of PtdIns(3,4,5)P3.”
BackgroundInfluentialOncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798 · cited 9×
“Recent pharmaceutical efforts in developing kinase inhibitors have resulted in a number of agents designed to inhibit the kinase components of these signalling pathways (mTOR, PI(3)K, RTKs, Raf and AKT).”
BackgroundInfluentialShah, O. J., Wang, Z., & Hunter, T. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 798 · cited 1×
“Subsequently, in both flies and mammals, TSC-deficient cells were found to have extremely low levels of AKT activation, even after growth-factor stimulation, despite high mTORC1 activit”
BackgroundRoux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750 · cited 1×
“and is also a substrate of the downstream ribosomal protein S6 kinase (RSK; Ser 1798”
BackgroundmTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes
Hresko, R. C., & Mueckler, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508361200 · Cited by 635
Regulation of Raf-1 by Direct Feedback Phosphorylation
Dougherty, M. K., Müller, J., Ritt, D. A., Zhou, M., Zhou, X. Z., Copeland, T. D., Conrads, T. P., Veenstra, T. D., Lu, K. P., & Morrison, D. K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.055 · Cited by 633 · cited 1×
“Negative feedback signals for Ras have been reported by means of ERK-mediated phosphorylatio”
BackgroundInactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
Sánchez‐Céspedes, M., Parrella, P., Esteller, M., Nomoto, S., Trink, B., Engles, J. M., Westra, W. H., Herman, J. G., & Sidransky, D. (2002) · PubMed · Cited by 612
Hypoxia-induced energy stress regulates mRNA translation and cell growth
Liu, L., Cash, T. P., Jones, R. G., Keith, B., Thompson, C. B., & Simon, M. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.010 · Cited by 607 · cited 1×
“AMPK inhibits mTOR at least in part by the direct phosphorylation of tuberin ( Box 3 ), and cells that lack tuberin retain activated mTORC1 under conditions of low glucose as well as hypoxi”
BackgroundHypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
NF1 Tumor Suppressor Gene Function
Cichowski, K., & Jacks, T. (2001) · Cell · doi:10.1016/s0092-8674(01)00245-8 · Cited by 601
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601 · cited 1×
“Interestingly, in NF1-deficient cells and tumours, endogenous levels of activated Ras were shown to induce mTOR activation through PI(3)K and AK”
BackgroundMutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin
Ding, Q., Xia, W., Liu, J.-C., Yang, J.-Y., Lee, D.-F., Xia, J., Bartholomeusz, G., Li, Y., Pan, Y., Li, Z., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.009 · Cited by 597 · cited 1×
“In addition, given the close similarity of the RSK and AKT kinase domains, it is possible that both can phosphorylate the same sites on some target proteins, such as GSK-3 (ref”
BackgroundCorradetti, M. N., Inoki, K., Bardeesy, N., DePinho, R. A., & Guan, K.-L. (2004) · Genes & Development · doi:10.1101/gad.1199104 · Cited by 560
Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity
Hahn-Windgassen, A., Nogueira, V., Chen, C.-C., Skeen, J. E., Sonenberg, N., & Hay, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502876200 · Cited by 539
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C. L., & Kwiatkowski, D. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17222 · Cited by 538 · cited 1×
“Finally, although evidence for the downregulation of PI(3)K signalling through S6K-mediated IRS1/IRS2 inhibition is compelling, other mechanisms are probably involved, including inhibition of RTK expressio”
BackgroundEngelman, J. A., Jänne, P. A., Mermel, C., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 493 · cited 1×
“For example, it was recently found that expression of ERBB3 predicted the therapeutic response of human non-small-cell lung tumour cell lines to the epidermal-growth-factor receptor (EGFR) inhibitor Iressa (gefitinib”
BackgroundSelf-citationLoss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Zhang, H., Cicchetti, G., Onda, H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317222 · Cited by 482
Manning, B. D. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408161 · Cited by 476 · cited 1×
“Similarly, prolonged activation of the PI(3)K pathway results in multiple forms of negative-feedback regulatio”
BackgroundGenetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467
She, Q.-B., Solit, D. B., Ye, Q., O’Reilly, K. E., Lobo, J., & Rosen, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 421 · cited 1×
“The cell-death effector BAD is also inhibited by both of these pathway”
BackgroundWild-Type and Mutant B-RAF Activate C-RAF through Distinct Mechanisms Involving Heterodimerization
Garnett, M. J., Rana, S., Paterson, H., Barford, D., & Marais, R. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.022 · Cited by 416 · cited 1×
“Tumour-associated mutations in B-raf have been found in some cases to cause constitutive heterodimerization with the related family member c-raf (also called Raf-1), which then activates downstream ERK signallin”
BackgroundThe PTEN, Mdm2, p53 tumor suppressor–oncoprotein network
Mayo, L. D., & Donner, D. B. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02166-7 · Cited by 410 · cited 1×
“or through phosphorylation of MDM2, a human oncogene product that degrades the p53 tumour suppresso”
BackgroundMice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours
Malliri, A., van der Kammen, R. A., Clark, K., van der Valk, M., Michiels, F., & Collard, J. G. (2002) · Nature · doi:10.1038/nature00848 · Cited by 384
Smith, E. M., Finn, S. G., Tee, A. R., Browne, G. J., & Proud, C. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414499200 · Cited by 355
Horman, S., Vertommen, D., Heath, R., Neumann, D., Mouton, V., Woods, A., Schlattner, U., Wallimann, T., Carling, D., Hue, L., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506850200 · Cited by 344
Lack of PTEN sequesters CHK1 and initiates genetic instability
Puc, J., Keniry, M., Li, H. S., Pandita, T. K., Choudhury, A. D., Memeo, L., Mansukhani, M., Murty, V. V. V. S., Gaciong, Z., Meek, S. E. M., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.009 · Cited by 328 · cited 1×
“, in which it may operate in part though direct phosphorylation of the Chk1 protein kinas”
BackgroundRodriguez-Viciana, P., Sabatier, C., & McCormick, F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.11.4943-4954.2004 · Cited by 327 · cited 1×
“However, it is not clear whether the Raf–ERK pathway is the most critical mediator of Ras-dependent tumorigenesis in all cell types; several other Ras effectors have been identified in the past ten year”
BackgroundTiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism
Lambert, J. M., Lambert, Q. T., Reuther, G. W., Malliri, A., Siderovski, D. P., Sondek, J., Collard, J. G., & Der, C. J. (2002) · Nature Cell Biology · doi:10.1038/ncb833 · Cited by 326
Activation of Akt/Protein Kinase B Overcomes a G 2 /M Cell Cycle Checkpoint Induced by DNA Damage
Kandel, E. S., Skeen, J., Majewski, N., Di Cristofano, A., Pandolfi, P. P., Feliciano, C. S., Gartel, A., & Hay, N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.22.7831-7841.2002 · Cited by 278 · cited 1×
“It has been implicated in a radiation-damage checkpoin”
BackgroundA Genetic Screen Identifies PITX1 as a Suppressor of RAS Activity and Tumorigenicity
Kolfschoten, I. G. M., van Leeuwen, B., Berns, K., Mullenders, J., Beijersbergen, R. L., Bernards, R., Voorhoeve, P. M., & Agami, R. (2005) · Cell · doi:10.1016/j.cell.2005.04.017 · Cited by 273 · cited 1×
“However, an RNA-interference screen for novel suppressors of Ras activity identified a transcription factor that promoted expression of the RasGAP RASAL1 (ref”
BackgroundA conditional feedback loop regulates Ras activity through EphA2
Macrae, M., Neve, R. M., Rodriguez-Viciana, P., Haqq, C., Yeh, J., Chen, C., Gray, J. W., & McCormick, F. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.005 · Cited by 260
New roles for the LKB1→AMPK pathway
Hardie, D. G. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.01.006 · Cited by 255
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2
Manning, B. D., Logsdon, M. N., Lipovsky, A. I., Abbott, D., Kwiatkowski, D. J., & Cantley, L. C. (2005) · Genes & Development · doi:10.1101/gad.1314605 · Cited by 235 · cited 1×
“Hyperactivation of mTOR–S6K signalling and inhibition of AKT signalling was also observed in benign haemangiomas that occur in Tsc2 p/− mic”
BackgroundSelf-citationBallif, B. A., Roux, P. P., Gerber, S. A., MacKeigan, J. P., Blenis, J., & Gygi, S. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409143102 · Cited by 211
BRAF alterations are associated with complex mutational profiles in malignant melanoma
Daniotti, M., Oggionni, M., Ranzani, T., Vallacchi, V., Campi, V., Di Stasi, D., Torre, G. D., Perrone, F., Luoni, C., Suardi, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207780 · Cited by 210
Manning, B. D., & Cantley, L. C. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310573 · Cited by 210
Self-citationCrucial Role of Phospholipase Cε in Chemical Carcinogen-Induced Skin Tumor Development
Bai, Y., Edamatsu, H., Maeda, S., Saito, H., Suzuki, N., Satoh, T., & Kataoka, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-3143 · Cited by 206
TOR Complex 2 Integrates Cell Movement during Chemotaxis and Signal Relay in Dictyostelium
Lee, S., Comer, F. I., Sasaki, A., McLeod, I. X., Duong, Y., Okumura, K., Yates, J. R., Parent, C. A., & Firtel, R. A. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-04-0342 · Cited by 196 · cited 1×
“Genetically, RNA interference (RNAi) for TORC2 components leads to a complete loss of phosphorylation at the AKT Ser 473 site in Drosophila , in Dictyostelium and in a variety of mammalian cell”
BackgroundLethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling
Radimerski, T., Montagne, J., Hemmings-Mieszczak, M., & Thomas, G. (2002) · Genes & Development · doi:10.1101/gad.239102 · Cited by 186 · cited 1×
“Subsequently, in both flies and mammals, TSC-deficient cells were found to have extremely low levels of AKT activation, even after growth-factor stimulation, despite high mTORC1 activit”
BackgroundRalGDS is required for tumor formation in a model of skin carcinogenesis
González-García, A., Pritchard, C. A., Paterson, H. F., Mavria, G., Stamp, G., & Marshall, C. J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.029 · Cited by 181
Granville, C. A., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1654 · Cited by 181 · cited 1×
“Rapamycin-based mTOR inhibitors have been introduced into several clinical trials in the past couple of year”
BackgroundSignalling networks that cause cancer
McCormick, F. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01668-2 · Cited by 162
The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation
McManus, E. J., Collins, B., Ashby, P. R., Prescott, A. R., Murray-Tait, V., Armit, L. J., Arthur, J. S. C., & Alessi, D. R. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600218 · Cited by 146
The TCL1 family of oncoproteins: co-activators of transformation
Teitell, M. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1672 · Cited by 131 · cited 1×
“Furthermore, the TCL1 oncogene from human T-cell leukaemias with 14q32-1 translocations has been shown to activate AK”
BackgroundBeginnings of a signal-transduction pathway for bioenergetic control of cell survival
Hammerman, P. S., Fox, C. J., & Thompson, C. B. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.09.008 · Cited by 129 · cited 1×
“It has been proposed that AKT directly stimulates glycolysis through the phosphorylation of 6-phosphofructo-2-kinase (PFK2), and fatty-acid synthesis through the phosphorylation of ATP citrate lyas”
BackgroundCommon mechanism for oncogenic activation of MLL by forkhead family proteins
So, C. W., & Cleary, M. L. (2003) · Blood · doi:10.1182/blood-2002-06-1785 · Cited by 120 · cited 1×
“Importantly, FOXOs are disrupted by translocations in some rhabdomyosarcomas and leukaemia”
BackgroundMechanisms of Tumor Suppression by the SCFFbw7
Minella, A. C., & Clurman, B. E. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2058 · Cited by 115
PTENGene Targeting Reveals a Radiation-Induced Size Checkpoint in Human Cancer Cells
Lee, C., Kim, J.-S., & Waldman, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1767 · Cited by 99 · cited 1×
“It has been implicated in a radiation-damage checkpoin”
BackgroundCrosstalk Between Pten and Ras Signaling Pathways in Tumor Development
To, M. D., Pérez‐Losada, J., Mao, J., & Balmain, A. (2005) · Cell Cycle · doi:10.4161/cc.4.9.2039 · Cited by 29
Ras effectors: Buying shares in Ras plc
Cullen, P. J. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00189-0 · Cited by 28
Crucial role of phospholipase Cε in chemical carcinogen-induced skin tumor development
白, 云. (2005) · Kobe University Repository Kernel (Kobe University) · Cited by 11
Cited by
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Self-citationEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
“Research over the past 40 years has uncovered some of the crucial players in the EGFR signal-transduction pathway, which can be roughly divided into two categories: the pro-survival arm of the pathway comprising the PI3K– mTOR (mammalian target of rapamycin)–Akt cascade, and the proliferative arm consisting of the Ras…”
BackgroundTargeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
“The evidence for their involvement and roles in Ras-mediated oncogenesis has been summarized in recent reviews (Repasky et al., 2004; Shaw and Cantley, 2006).”
BackgroundMolecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
“In particular, the phosphoinositide 3-kinase (PI3K)– AKT pathway and the Ras–ERK (extracellular signal-regulated kinase) pathwa”
BackgroundTargeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Metadata
- Authors
- Shaw, R. J., & Cantley, L. C.
- Affiliations
- Salk Institute for Biological Studies (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 424-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2144323242
- Cited by
- 2,019
- References
- 86
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 48 · 2023: 68 · 2022: 68 · 2021: 77 · 2020: 91 · 2019: 74 · 2018: 95 · 2017: 99 · 2016: 109 · 2015: 146 · 2014: 119 · 2013: 153 · 2012: 143
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- Ras signaling, PI3K signaling, mTOR signaling, tumour cell growth, nutrient sensing, amino acids, glucose, oxygen availability, cancer mutations, carcinogenesis, cell survival
- MeSH terms
- Animals, Humans, Neoplasms, Protein Kinases, Signal Transduction, ras Proteins, Phosphatidylinositol 3-Kinases, Cell Growth Processes, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.